BioWorld

May 29, 2008

Struggling Sonus Building Value, Pipeline via OncoGenex Merger

Sonus Pharmaceuticals Inc., which has fought to rebuild shareholder value following the failure of lead drug Tocosol Paclitaxel in a pivotal Phase III trial in September, is bolstering its clinical pipeline with the acquisition of Canadian biotech OncoGenex Technologies Inc. (BioWorld Today) Read More

Wall Street Reaction to Advexin Data Drops Introgen Shares

For Inflammatory Bowel Disease, Spoonful of Sugar is the Medicine

Hughes Institute Funding $600M in Pure Science

Denosumab Trumps Fosamax in Phase III Bone Density Study

Lexicon Cuts 100 Jobs to Focus on Pipeline

Other News To Note

Clinic Roundup

Financing Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...